Lifecore Biomedical Inc
NASDAQ:LFCR
Lifecore Biomedical Inc
Cash & Cash Equivalents
Lifecore Biomedical Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Cash & Cash Equivalents
$9.5m
|
CAGR 3-Years
105%
|
CAGR 5-Years
43%
|
CAGR 10-Years
7%
|
|
|
Hershey Co
NYSE:HSY
|
Cash & Cash Equivalents
$730.7m
|
CAGR 3-Years
30%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
General Mills Inc
NYSE:GIS
|
Cash & Cash Equivalents
$521.3m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Kellogg Co
NYSE:K
|
Cash & Cash Equivalents
$694m
|
CAGR 3-Years
34%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Cash & Cash Equivalents
$1.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Cash & Cash Equivalents
$1.4B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.5m
USD
Based on the financial report for Nov 24, 2024, Lifecore Biomedical Inc's Cash & Cash Equivalents amounts to 9.5m USD.
What is Lifecore Biomedical Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
7%
Over the last year, the Cash & Cash Equivalents growth was 194%. The average annual Cash & Cash Equivalents growth rates for Lifecore Biomedical Inc have been 105% over the past three years , 43% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet